Evidence map›Paper›PMID 40969388›Full record

ArticleMaterials today. Bio2025

Dual enzyme-driven redox homeostasis disruption with ultrasmall Pt-decorated MoS

Mengmeng Dong, Yimo Wang, Lidong Cao, Xiaobin Fei, Junjie Qian, Qingqing Wu, Lu Zhou, Yueqin Zhang, Wei Duan, Chengwu Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengmeng DongGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Yimo WangDepartment of Radiation Oncology, Tohoky University, Sendai, Japan.
Lidong CaoGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Xiaobin FeiGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Junjie QianGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Qingqing WuDepartment of Surgery, Hangzhou Normal University Second Clinical Medical College, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Lu ZhouGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Yueqin ZhangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Wei DuanSchool of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Chengwu ZhangGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Changwei DouGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent clinical task for developing novel and precise therapies to enhance the treatment efficiency of hepatocellular carcinoma (HCC). Ferroptosis, a form of non-apoptotic regulated cell death, plays a significant role in improving cancer treatment outcomes. However, the robust antioxidant defense system within the tumor microenvironment (TME) severely impacts the ferroptosis efficacy. Nanozymes are emerging as promising candidates for inducing ferroptosis, but constructing novel nanozymes with high catalytic efficiency and multiple activities to amplify ferroptosis's therapeutic effects remains challenging. Here, we have judiciously fabricated a bimetallic nanozyme of ultrasmall Pt-decorated MoS

Indexed as

Ferroptosis therapyHepatocellular carcinomaNanozymePhotothermal therapyTumor microenvironment

Identifiers

PMID40969388
PMCPMC12441709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.